28 min
Dr Jewel Mullen Discusses NASEM's Framework For an Equitable Distribution of a COVID-19 Vaccine Managed Care Cast
-
- Science
Recently released vaccine data from both Pfizer and Moderna indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). But both vaccines are still a long way from becoming readily available to the wider public, prompting the question, who should be prioritized once doses become available?
To provide guidance on this front, The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) requested The National Academies of Science, Engineering, and Medicine (NASEM) to construct a framework assisting US policymakers and global health communities to plan for an equitable allocation of a COVID-19 vaccine.
On this episode of Managed Care Cast, we speak with Jewel Mullen, (MD, MPH) the associate dean for health equity and associate professor of population health and internal medicine at the University of Texas at Austin, Dell Medical School. Mullen is the former principal deputy assistant secretary for health in the U.S. Department of Health and Human Services (HHS) and a member of the National Academies committee which developed the framework for vaccine allocation.
Mullen discusses criteria used to prioritize vaccine recipients, barriers to equitable distribution, and the role of misinformation in the push for an effective COVID-19 vaccine.
Read more:
Pfizer Says Vaccine 90% Effective; Biden Team Announces COVID-19 Transition Panel: https://www.ajmc.com/view/pfizer-says-vaccine-90-effective-biden-team-announces-covid-19-transition-panel
Study Backs Decision to Move Forward With Pfizer Vaccine Candidate: https://www.ajmc.com/view/study-backs-decision-to-move-forward-with-pfizer-vaccine-candidate
Moderna SARS-CoV-2 Vaccine Elicits Response in Older Adults: https://www.ajmc.com/view/moderna-sars-cov-2-vaccine-elicits-response-in-older-adults
Dr Maura Abbott: Talk to Your Patients About Their Vaccine Fears: https://www.ajmc.com/view/dr-maura-abbott-talk-to-your-patients-about-their-vaccine-fears
Dr Maura Abbott: COVID-19 Vaccine Development Process Is Safe Despite a Quicker Timeline: https://www.ajmc.com/view/dr-maura-abbott-covid-19-vaccine-development-process-is-safe-despite-a-quicker-timeline
Dr Victoria Smith on Experience Taking Part in a COVID-19 Vaccine Trial: https://www.ajmc.com/view/dr-victoria-smith-on-experience-taking-part-in-a-covid-19-vaccine-trial
Recently released vaccine data from both Pfizer and Moderna indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). But both vaccines are still a long way from becoming readily available to the wider public, prompting the question, who should be prioritized once doses become available?
To provide guidance on this front, The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) requested The National Academies of Science, Engineering, and Medicine (NASEM) to construct a framework assisting US policymakers and global health communities to plan for an equitable allocation of a COVID-19 vaccine.
On this episode of Managed Care Cast, we speak with Jewel Mullen, (MD, MPH) the associate dean for health equity and associate professor of population health and internal medicine at the University of Texas at Austin, Dell Medical School. Mullen is the former principal deputy assistant secretary for health in the U.S. Department of Health and Human Services (HHS) and a member of the National Academies committee which developed the framework for vaccine allocation.
Mullen discusses criteria used to prioritize vaccine recipients, barriers to equitable distribution, and the role of misinformation in the push for an effective COVID-19 vaccine.
Read more:
Pfizer Says Vaccine 90% Effective; Biden Team Announces COVID-19 Transition Panel: https://www.ajmc.com/view/pfizer-says-vaccine-90-effective-biden-team-announces-covid-19-transition-panel
Study Backs Decision to Move Forward With Pfizer Vaccine Candidate: https://www.ajmc.com/view/study-backs-decision-to-move-forward-with-pfizer-vaccine-candidate
Moderna SARS-CoV-2 Vaccine Elicits Response in Older Adults: https://www.ajmc.com/view/moderna-sars-cov-2-vaccine-elicits-response-in-older-adults
Dr Maura Abbott: Talk to Your Patients About Their Vaccine Fears: https://www.ajmc.com/view/dr-maura-abbott-talk-to-your-patients-about-their-vaccine-fears
Dr Maura Abbott: COVID-19 Vaccine Development Process Is Safe Despite a Quicker Timeline: https://www.ajmc.com/view/dr-maura-abbott-covid-19-vaccine-development-process-is-safe-despite-a-quicker-timeline
Dr Victoria Smith on Experience Taking Part in a COVID-19 Vaccine Trial: https://www.ajmc.com/view/dr-victoria-smith-on-experience-taking-part-in-a-covid-19-vaccine-trial
28 min